| Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making L Malcovati, MGD Porta, C Pascutto, R Invernizzi, M Boni, E Travaglino, ... Journal of Clinical Oncology 23 (30), 7594-7603, 2005 | 1124 | 2005 |
| A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and … F Passamonti, F Cervantes, AM Vannucchi, E Morra, E Rumi, A Pereira, ... Blood, The Journal of the American Society of Hematology 115 (9), 1703-1708, 2010 | 1073 | 2010 |
| CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons A Tefferi, TL Lasho, CM Finke, RA Knudson, R Ketterling, CH Hanson, ... Leukemia 28 (7), 1472-1477, 2014 | 688 | 2014 |
| A prognostic model to predict survival in 867 World Health Organization–defined essential thrombocythemia at diagnosis: a study by the International Working Group on … F Passamonti, J Thiele, F Girodon, E Rumi, A Carobbio, H Gisslinger, ... Blood, The Journal of the American Society of Hematology 120 (6), 1197-1201, 2012 | 326 | 2012 |
| A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis F Passamonti, T Giorgino, B Mora, P Guglielmelli, E Rumi, M Maffioli, ... Leukemia 31 (12), 2726-2731, 2017 | 314 | 2017 |
| EZH2 mutational status predicts poor survival in myelofibrosis P Guglielmelli, F Biamonte, J Score, C Hidalgo-Curtis, F Cervantes, ... Blood, The Journal of the American Society of Hematology 118 (19), 5227-5234, 2011 | 306 | 2011 |
| Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients A Tefferi, EA Wassie, P Guglielmelli, N Gangat, AA Belachew, TL Lasho, ... American journal of hematology 89 (8), E121-E124, 2014 | 258 | 2014 |
| Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis P Guglielmelli, A Pacilli, G Rotunno, E Rumi, V Rosti, F Delaini, M Maffioli, ... Blood, The Journal of the American Society of Hematology 129 (24), 3227-3236, 2017 | 208 | 2017 |
| Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients A Martínez-Trillos, A Gaya, M Maffioli, E Arellano-Rodrigo, X Calvo, ... Annals of hematology 89, 1233-1237, 2010 | 208 | 2010 |
| Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis N Kröger, T Giorgino, BL Scott, M Ditschkowski, H Alchalby, F Cervantes, ... Blood, The Journal of the American Society of Hematology 125 (21), 3347-3350, 2015 | 195 | 2015 |
| Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome MG Della Porta, L Malcovati, R Invernizzi, E Travaglino, C Pascutto, ... Leukemia 20 (4), 549-555, 2006 | 169 | 2006 |
| Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome L Malcovati, MG Della Porta, M Lunghi, C Pascutto, L Vanelli, ... Leukemia 19 (5), 776-783, 2005 | 161 | 2005 |
| Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts F Passamonti, M Maffioli, F Cervantes, AM Vannucchi, E Morra, T Barbui, ... Blood, The Journal of the American Society of Hematology 123 (12), 1833-1835, 2014 | 113 | 2014 |
| Mutation-enhanced international prognostic scoring system (MIPSS) for primary myelofibrosis: an AGIMM & IWG-MRT project AM Vannucchi, P Guglielmelli, G Rotunno, C Pascutto, A Pardanani, ... Blood 124 (21), 405, 2014 | 98 | 2014 |
| Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: a study on 359 patients of the AGIMM group G Rotunno, A Pacilli, V Artusi, E Rumi, M Maffioli, F Delaini, G Brogi, ... American journal of hematology 91 (7), 681-686, 2016 | 91 | 2016 |
| JAK inhibitor in CALR-mutant myelofibrosis. F Passamonti, D Caramazza, M Maffioli The New England journal of medicine 370 (12), 1168-1169, 2014 | 79 | 2014 |
| Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia M Maffioli, M Camós, A Gaya, JC Hernández-Boluda, A Álvarez-Larrán, ... Leukemia research 35 (8), 1014-1019, 2011 | 69 | 2011 |
| Update from the latest WHO classification of MPNs: a user’s manual F Passamonti, M Maffioli Hematology 2014, the American Society of Hematology Education Program Book …, 2016 | 67 | 2016 |
| Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies F Passamonti, M Maffioli, D Caramazza, M Cazzola Oncotarget 2 (6), 485, 2011 | 67 | 2011 |
| Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases F Dentali, W Ageno, E Rumi, I Casetti, D Poli, U Scoditti, M Maffioli, ... Thrombosis Research 134 (1), 41-43, 2014 | 60 | 2014 |
